TC Biopharm(TCBP.US)

Company Encyclopedia
View More
name
TC Biopharm
TCBP.US
TC Biopharm (Holdings) Plc, a clinical-stage biopharmaceutical company, focuses on the development of immunotherapy products based on its allogeneic gamma delta T cell platform. Its product pipeline includes OmnImmune, an allogeneic unmodified gamma-delta T cell therapy product under Phase 2/3 trails for the treatment of acute myeloid leukemia; and ImmuniStim, an unmodified cell therapy to treat viral infections as well as cancers. The company was founded in 2013 and is headquartered in Motherwell, the United Kingdom.
1.896 T
TCBP.USMarket value -Rank by Market Cap -/-

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    TC BioPharm Delists American Depositary Shares

    TC BioPharm (Holdings) plc has filed to deregister and delist its American Depositary Shares (ADS), each representing 4,000 Ordinary shares. The decision impacts these ADS securities, with 18 holders of record. The filing was signed by CFO Martin Thorp. This information was published via the U.S. SEC's EDGAR system on December 3, 2025.

    Reuters·
    US
    TCBP
    0.00%
    Reuters·
    US
    TCBP
    0.00%

    CytoMed Therapeutics Finalizes Acquisition of T Cell Technology for Cancer Treatment in China and India

    CytoMed Therapeutics Limited has completed the acquisition of TC BioPharm Limited’s gamma delta T cell technology, TCB-002, to enhance cancer treatment in China and India. This acquisition aligns with CytoMed’s strategy to establish a non-viral allogeneic gamma delta T cell immunotherapy platform. The technology, which has completed a Phase I clinical trial in Europe, will be adapted for use in China and India. The most recent analyst rating on GDTC stock is a Hold with a $2.00 price target.

    Tip Ranks·
    US
    TCBP
    0.00%
    Tip Ranks·
    US
    TCBP
    0.00%

    TC BioPharm Appoints Interim Liquidators and Plans SEC Deregistration

    TC BioPharm (Holdings) plc has appointed Ben Cairns and Michael Magnay as interim liquidators and plans to deregister its American Depositary Shares with the SEC, suspending its obligation to file periodic reports. The company has authorized Addleshaw Goddard LLP to formalize the liquidators' appointment. This information was published via the SEC's EDGAR system.

    Reuters·
    US
    TCBP
    0.00%
    Reuters·
    US
    TCBP
    0.00%

    CytoMed Therapeutics Submits Cash Bid to Acquire TC BioPharm Assets

    CytoMed Therapeutics Limited has made a cash bid to acquire selected assets of TC BioPharm Limited, which recently appointed joint administrators. Both companies specialize in donor-derived allogeneic gamma delta T cell therapies for cancer. CytoMed aims to enhance its capabilities in cell-based immunotherapies and believes that acquiring TC BioPharm’s assets will bolster its expertise and support its mission to provide new therapeutic options for patients with unmet medical needs.

    Reuters·
    US
    TCBP
    0.00%
    Reuters·
    US
    TCBP
    0.00%

    TC BioPharm Limited Enters Administration; Joint Administrators Seek Sale of Subsidiary's Assets

    TC BioPharm Limited has entered administration, with joint administrators Michael Magnay and Rob Croxen appointed to seek a sale of its business and assets, including intellectual property and R&D assets. TC BioPharm (Holdings) plc remains operational and is not affected by the administration process.

    Reuters·
    US
    TCBP
    0.00%
    Reuters·
    US
    TCBP
    0.00%
    © 2026 Longbridge｜Disclaimer